Stock Price
14.77
Daily Change
-0.28 -1.86%
Monthly
9.41%
Yearly
33.67%
Q1 Forecast
14.47

Amarin reported $-1.7M in Operating Profit for its fiscal quarter ending in September of 2025.





Operating Profit Change Date
AbbVie USD 4.58B 1.13B Sep/2025
Alnylam Pharmaceuticals USD -29.96M 13.76M Sep/2025
Amarin USD -1.7M 8.47M Sep/2025
AstraZeneca USD -1.5B 5.01B Sep/2025
DBV Technologies USD -34.28M 6.83M Sep/2025
GlaxoSmithKline GBP 2.79B 764M Sep/2025
Halozyme Therapeutics USD 217.92M 15.48M Sep/2025
Ionis Pharmaceuticals USD -160.18M 300.02M Sep/2025
Neurocrine Biosciences USD 239.3M 93.7M Sep/2025
Novartis USD 4.5B 363M Sep/2025